Login Register Cart 0
Generic placeholder image

Drug Delivery Letters

Editor-in-Chief

ISSN (Print): 2210-3031
ISSN (Online): 2210-304X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development and Evaluation of Bioresponsive Tablets of a Selective COX-2 Inhibitor for Colonic Delivery

Author(s): Srushti Tambe and Namita Desai*

Volume 10, Issue 1, 2020

Page: [72 - 83] Pages: 12

DOI: 10.2174/2210303109666190828095726

Price: $65

Abstract

Background: We report the effectiveness of a targeted delivery system containing Meloxicam using polysaccharides for the treatment of colorectal cancer. We also propose a novel biorelevant dissolution method to overcome drawbacks of existing dissolution methodologies of polysaccharidebased systems. The proposed method includes a mixture of probiotics cultured under anaerobic conditions in the presence of prebiotic in the in vitro dissolution study to surrogate colonic conditions. Polysaccharide- based system can be simple, safe and effective drug delivery system to target drugs to colon.

Methods: Press-coated tablets of Meloxicam were prepared by direct compression using various polysaccharides, such as xanthan gum, guar gum and pectin as coating polysaccharides. Developed tablets were evaluated for physical parameters, lag phase and in vitro drug release. Developed probioticsbased dissolution method was validated and explored for versatility using other polysaccharides.

Results: Press-coated tablets of Meloxicam were successfully developed exhibiting targeted delivery to the colon using guar gum as coat and releasing more than 80% of drug in simulated colonic fluid. The developed probiotics based dissolution method may prove to be useful as a bio-relevant and discriminatory method.

Conclusion: Developed Meloxicam tablets press-coated with guar gum can be taken orally for treatment or as an adjuvant therapy in colon cancer. Polymers used in this formulation are abundant, nontoxic, biodegradable and inexpensive which make this a a very promising approach for the treatment of different colonic diseases. The proposed biorelevant, animal sparing, probiotics based dissolution medium was found to be versatile to study drug release from other polysaccharide based formulations for colonic delivery.

Keywords: Polysaccharides, guar gum, Meloxicam, probiotics, biorelevant medium, in vitro dissolution.

« Previous
Graphical Abstract

[1]
Favoriti, P.; Carbone, G.; Greco, M.; Pirozzi, F.; Pirozzi, R.E.M.; Corcione, F. Worldwide burden of colorectal cancer: a review. Updates Surg., 2016, 68(1), 7-11.
[http://dx.doi.org/10.1007/s13304-016-0359-y] [PMID: 27067591]
[2]
Distel, M.; Mueller, C.; Bluhmki, E.; Fries, J. Safety of meloxicam: a global analysis of clinical trials.Rheumatology., 1996. 35(suppl_1), 68-77.
[http://dx.doi.org/10.1093/rheumatology/35.suppl_1.68]
[3]
Distel, M.; Mueller, C.; Bluhmki, E. Global analysis of gastrointestinal safety of a new NSAID, meloxicam.Side Effects of Anti-Inflammatory Drugs IV; Springer, 1997, pp. 183-193.http://dx.doi.org/http://dx.doi.org/10.1007/978-94-011-5394-2_19
[4]
Goldman, A.P.; Williams, C.S.; Sheng, H.; Lamps, L.W.; Williams, V.P.; Pairet, M.; Morrow, J.D.; DuBois, R.N. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis, 1998, 19(12), 2195-2199.
[http://dx.doi.org/10.1093/carcin/19.12.2195] [PMID: 9886578]
[5]
Zhang, N.; Tao, K.; Huang, T. Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line HT-29. J. Huazhong Univ. Sci. Technolog. Med. Sci., 2007, 27(4), 399-402.
[http://dx.doi.org/10.1007/s11596-007-0412-7] [PMID: 17828495]
[6]
Davies, N.M.; Skjodt, N.M. Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin. Pharmacokinet., 1999, 36(2), 115-126.
[http://dx.doi.org/10.2165/00003088-199936020-00003] [PMID: 10092958]
[7]
Sinha, V.R.; Kumria, R. Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci., 2003, 18(1), 3-18.
[http://dx.doi.org/10.1016/S0928-0987(02)00221-X] [PMID: 12554067]
[8]
Abedini, F.; Ebrahimi, M.; Roozbehani, A.H.; Domb, A.J.; Hosseinkhani, H. Overview on natural hydrophilic polysaccharide polymers in drug delivery. Polym. Adv. Technol., 2018, 29(10), 2564-2573.
[http://dx.doi.org/10.1002/pat.4375]
[9]
Mottaghitalab, F.; Farokhi, M.; Shokrgozar, M.A.; Atyabi, F.; Hosseinkhani, H. Silk fibroin nanoparticle as a novel drug delivery system. J. Control. Release, 2015, 206, 161-176.
[http://dx.doi.org/10.1016/j.jconrel.2015.03.020] [PMID: 25797561]
[10]
Mottaghitalab, F.; Hosseinkhani, H.; Shokrgozar, M.A.; Mao, C.; Yang, M.; Farokhi, M. Silk as a potential candidate for bone tissue engineering. J. Control. Release, 2015, 215, 112-128.
[http://dx.doi.org/10.1016/j.jconrel.2015.07.031] [PMID: 26254197]
[11]
Abedini, F.; Hosseinkhani, H.; Ismail, M.; Domb, A.J.; Omar, A.R.; Chong, P.P.; Hong, P-D.; Yu, D-S.; Farber, I-Y. Cationized dextran nanoparticle-encapsulated CXCR4-siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer. Int. J. Nanomedicine, 2012, 7, 4159-4168.
[PMID: 22888250]
[12]
Khan, W.; Hosseinkhani, H.; Ickowicz, D.; Hong, P-D.; Yu, D-S.; Domb, A.J. Polysaccharide gene transfection agents. Acta Biomater., 2012, 8(12), 4224-4232.
[http://dx.doi.org/10.1016/j.actbio.2012.09.022] [PMID: 23022542 ]
[13]
Hosseinkhani, H.; Abedini, F.; Ou, K.L.; Domb, A.J. Polymers in gene therapy technology. Polym. Adv. Technol., 2015, 26(2), 198-211.
[http://dx.doi.org/10.1002/pat.3432]
[14]
Chiang, C.H.; Hosseinkhani, H.; Cheng, W.S.; Chen, C.W.; Wang, C.H.; Lo, Y.L. Improving drug loading efficiency and delivery performance of micro–and nanoparticle preparations through optimising formulation variables. Int. J. Nanotechnol., 2013, 10(10-11), 996-1006.
[http://dx.doi.org/10.1504/IJNT.2013.058125]
[15]
Hensel, A.; Meier, K. Pectins and xyloglucans exhibit antimutagenic activities against nitroaromatic compounds. Planta Med., 1999, 65(5), 395-399.
[http://dx.doi.org/10.1055/s-1999-14013] [PMID: 10418322]
[16]
Gómez, B.; Gullón, B.; Remoroza, C.; Schols, H.A.; Parajó, J.C.; Alonso, J.L. Purification, characterization, and prebiotic properties of pectic oligosaccharides from orange peel wastes. J. Agric. Food Chem., 2014, 62(40), 9769-9782.
[http://dx.doi.org/10.1021/jf503475b] [PMID: 25207862]
[17]
Chen, C-H.; Sheu, M-T.; Chen, T-F.; Wang, Y-C.; Hou, W-C.; Liu, D-Z.; Chung, T-C.; Liang, Y-C. Suppression of endotoxin-induced proinflammatory responses by citrus pectin through blocking LPS signaling pathways. Biochem. Pharmacol., 2006, 72(8), 1001-1009.
[http://dx.doi.org/10.1016/j.bcp.2006.07.001] [PMID: 16930561]
[18]
Giannini, E.G.; Mansi, C.; Dulbecco, P.; Savarino, V. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. Nutrition, 2006, 22(3), 334-342.
[http://dx.doi.org/10.1016/j.nut.2005.10.003] [PMID: 16413751]
[19]
Bose, S.; Bogner, R.H. Solventless pharmaceutical coating processes: a review. Pharm. Dev. Technol., 2007, 12(2), 115-131.
[http://dx.doi.org/10.1080/10837450701212479] [PMID: 17510883]
[20]
Turkoglu, M.; Ugurlu, T. In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery. Eur. J. Pharm. Biopharm., 2002, 53(1), 65-73.
[http://dx.doi.org/10.1016/S0939-6411(01)00225-9] [PMID: 11777754]
[21]
Ugurlu, T.; Turkoglu, M.; Gurer, U.S.; Akarsu, B.G. Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture. Eur. J. Pharm. Biopharm., 2007, 67(1), 202-210.
[http://dx.doi.org/10.1016/j.ejpb.2007.01.016] [PMID: 17337171]
[22]
Wakerly, Z.; Fell, J.T.; Attwood, D.; Parkins, D. Pectin/ethylcellulose film coating formulations for colonic drug delivery. Pharm. Res., 1996, 13(8), 1210-1212.
[http://dx.doi.org/10.1023/A:1016016404404] [PMID: 8865314]
[23]
Rubinstein, A.; Radai, R. In vitro and in vivo analysis of colon specificity of calcium pectinate formulations. Eur. J. Pharm. Biopharm., 1995, 41(5), 291-295.
[24]
Krishnaiah, Y.; Satyanarayana, S.; Prasad, Y.R.; Rao, S.N. Evaluation of guar gum as a compression coat for drug targeting to colon. Int. J. Pharm., 1998, 171(2), 137-146.
[http://dx.doi.org/10.1016/S0378-5173(98)00172-0]
[25]
Sinha, V.R.; Mittal, B.R.; Kumria, R. In vivo evaluation of time and site of disintegration of polysaccharide tablet prepared for colon-specific drug delivery. Int. J. Pharm., 2005, 289(1-2), 79-85.
[http://dx.doi.org/10.1016/j.ijpharm.2004.10.019] [PMID: 15652201]
[26]
Omwancha, W.; Kouba, C.; Yelamanchili, S.; Neau, S.H. Colon-specific drug delivery using ethylcellulose and chitosan in the coat of compression-coated tablets. Drug Dev. Ind. Pharm., 2011, 37(8), 945-953.
[http://dx.doi.org/10.3109/03639045.2010.551773] [PMID: 21417614]
[27]
Takeuchi, H.; Yasuji, T.; Yamamoto, H.; Kawashima, Y. Spray-dried lactose composite particles containing an ion complex of alginate-chitosan for designing a dry-coated tablet having a time-controlled releasing function. Pharm. Res., 2000, 17(1), 94-99.
[http://dx.doi.org/10.1023/A:1007530927887] [PMID: 10714615]
[28]
Sirkiä, T.; Salonen, H.; Veski, P.; Jürjenson, H.; Marvola, M. Biopharmaceutical evaluation of new prolonged-release press-coated ibuprofen tablets containing sodium alginate to adjust drug release. Int. J. Pharm., 1994, 107(3), 179-187.
[http://dx.doi.org/10.1016/0378-5173(94)90432-4]
[29]
Moussa, I.S.; Cartilier, L.H. Evaluation of cross-linked amylose press-coated tablets for sustained drug delivery. Int. J. Pharm., 1997, 149(2), 139-149.
[http://dx.doi.org/10.1016/S0378-5173(97)04864-3]
[30]
Maggi, L.; Massolini, G.; De Lorenzi, E.; Conte, U.; Caccialanza, G. Evaluation of stereoselective dissolution of verapamil hydrochloride from matrix tablets press-coated with chiral excipients. Int. J. Pharm., 1996, 136(1-2), 43-51.
[http://dx.doi.org/10.1016/0378-5173(96)04487-0]
[31]
Wilson, P.J.; Basit, A.W. Exploiting gastrointestinal bacteria to target drugs to the colon: an in vitro study using amylose coated tablets. Int. J. Pharm., 2005, 300(1-2), 89-94.
[http://dx.doi.org/10.1016/j.ijpharm.2005.05.010] [PMID: 16023805]
[32]
Krishna, K.; Tanaji, N.; Kiran, B.; Pradeep, D. Studies on development of oral colon targeted drug delivery system of locust bean and xanthan gum Int. J. Green Pharm., 2007, 1(1)
[33]
Chakravorty, A.; Barman, G.; Mukherjee, S.; Sa, B. Effect of carboxymethylation on rheological and drug release characteristics of locust bean gum matrix tablets. Carbohydr. Polym., 2016, 144, 50-58.
[http://dx.doi.org/10.1016/j.carbpol.2016.02.010] [PMID: 27083792]
[34]
Singh, S.K.; Yadav, A.K.; Prudhviraj, G.; Gulati, M.; Kaur, P.; Vaidya, Y. A novel dissolution method for evaluation of polysaccharide based colon specific delivery systems: A suitable alternative to animal sacrifice. Eur. J. Pharm. Sci., 2015, 73, 72-80.
[http://dx.doi.org/10.1016/j.ejps.2015.03.012] [PMID: 25829049]
[35]
Kotla, N.G.; Gulati, M.; Singh, S.K.; Shivapooja, A. Facts, fallacies and future of dissolution testing of polysaccharide based colon-specific drug delivery. J. Control. Release, 2014, 178, 55-62.
[http://dx.doi.org/10.1016/j.jconrel.2014.01.010] [PMID: 24440665]
[36]
Tambe, S.M.; Desai, N.D. Colonic Bacterial Enzymes: Pharmaceutical Significance and Applications.Research Advancements in Pharmaceutical, Nutritional, and Industrial Enzymology; IGI Global, 2018, pp. 71-99.
[http://dx.doi.org/10.4018/978-1-5225-5237-6.ch004 ]
[37]
Kotla, N.G.; Singh, S.; Maddiboyina, B.; Sunnapu, O.; Webster, T.J. A novel dissolution media for testing drug release from a nanostructured polysaccharide-based colon specific drug delivery system: an approach to alternative colon media. Int. J. Nanomedicine, 2016, 11, 1089-1095.
[PMID: 27051284]
[38]
Engelhardt, G.; Homma, D.; Schlegel, K.; Utzmann, R.; Schnitzler, C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm. Res., 1995, 44(10), 423-433.
[http://dx.doi.org/10.1007/BF01757699] [PMID: 8564518]
[39]
Patoia, L.; Santucci, L.; Furno, P.; Dionisi, M.; Dell'Orso, S.; Romagnoli, M.; Sattarinia, A.; Marini, M. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volun-teers Rheumatology. 1996, 35 ((suppl_1)), 61-67.
[40]
Krishnaiah, Y.S.; Satyanarayana, S.; Prasad, Y.V. Studies of guar gum compression-coated 5-aminosalicylic acid tablets for colon-specific drug delivery. Drug Dev. Ind. Pharm., 1999, 25(5), 651-657.
[http://dx.doi.org/10.1081/DDC-100102221] [PMID: 10219535]
[41]
Fukui, E.; Uemura, K.; Kobayashi, M. Studies on applicability of press-coated tablets using hydroxypropylcellulose (HPC) in the outer shell for timed-release preparations. J. Control. Release, 2000, 68(2), 215-223.
[http://dx.doi.org/10.1016/S0168-3659(00)00261-3] [PMID: 10925130]
[42]
Veerareddy, P.R.; Vemula, S.K. Formulation, evaluation and pharmacokinetics of colon targeted pulsatile system of flurbiprofen. J. Drug Target., 2012, 20(8), 703-714.
[http://dx.doi.org/10.3109/1061186X.2012.712131] [PMID: 22845842]
[43]
Kaerger, J.S.; Edge, S.; Price, R. Influence of particle size and shape on flowability and compactibility of binary mixtures of paracetamol and microcrystalline cellulose. Eur. J. Pharm. Sci., 2004, 22(2-3), 173-179.
[http://dx.doi.org/10.1016/j.ejps.2004.03.005] [PMID: 15158902]
[44]
Wilson, C.G. The transit of dosage forms through the colon. Int. J. Pharm., 2010, 395(1-2), 17-25.
[http://dx.doi.org/10.1016/j.ijpharm.2010.04.044] [PMID: 20576492]
[45]
Lin, S-Y.; Kawashima, Y. Current status and approaches to developing press-coated chronodelivery drug systems. J. Control. Release, 2012, 157(3), 331-353.
[http://dx.doi.org/10.1016/j.jconrel.2011.09.065] [PMID: 21968338]
[46]
Maiti, P.K.; Haldar, J.; Mukherjee, P.; Dey, R. Anaerobic culture on growth efficient bi-layered culture plate in a modified candle jar using a rapid and slow combustion system. Indian J. Med. Microbiol., 2013, 31(2), 173-176.
[PMID: 23867675]
[47]
USP, G. C. 1092. The Dissolution Procedure Development and Validation USP 34-NF, 292011.
[48]
Cole, G.C. Introduction and overview of pharmaceutical coating.Pharmaceutical coating technology; CRC Press, 1995, pp. 11-15.http://dx.doi.org/http://dx.doi.org/10.3109/9780203014356-2
[49]
Aulton, M.; Taylor, K. Pharmaceutics-The science of dosage form design; Churchill Livingstone: London, England, 2002, pp. 340-348.
[50]
Thoorens, G.; Krier, F.; Leclercq, B.; Carlin, B.; Evrard, B. Microcrystalline cellulose, a direct compression binder in a quality by design environment--a review. Int. J. Pharm., 2014, 473(1-2), 64-72.
[http://dx.doi.org/10.1016/j.ijpharm.2014.06.055] [PMID: 24993785]
[51]
Wang, J.; Wen, H.; Desai, D. Lubrication in tablet formulations. Eur. J. Pharm. Biopharm., 2010, 75(1), 1-15.
[http://dx.doi.org/10.1016/j.ejpb.2010.01.007] [PMID: 20096779]
[52]
Zuurman, K.; Van der Voort Maarschalk, K.; Bolhuis, G.K. Effect of magnesium stearate on bonding and porosity expansion of tablets produced from materials with different consolidation properties. Int. J. Pharm., 1999, 179(1), 107-115.
[http://dx.doi.org/10.1016/S0378-5173(98)00389-5] [PMID: 10053207]
[53]
Khullar, P.; Khar, R.K.; Agarwal, S.P. Evaluation of guar gum in the preparation of sustained-release matrix tablets. Drug Dev. Ind. Pharm., 1998, 24(11), 1095-1099.
[http://dx.doi.org/10.3109/03639049809089955] [PMID: 9876566]
[54]
Patel, J.; Karve, M.; Patel, N.K. Guar gum: a versatile material for pharmaceutical industries. Int. J. Pharm. Pharm. Sci., 2014, 6(8), 13-19.
[55]
Mudgil, D.; Barak, S.; Khatkar, B.S. Guar gum: processing, properties and food applications-A Review. J. Food Sci. Technol., 2014, 51(3), 409-418.
[http://dx.doi.org/10.1007/s13197-011-0522-x] [PMID: 24587515]
[56]
Sriamornsak, P. Chemistry of pectin and its pharmaceutical uses: A review. Silpakorn Univ. Int. J., 2003, 3(1-2), 206-228.
[57]
Thakur, B.R.; Singh, R.K.; Handa, A.K.; Rao, M. Chemistry and uses of pectin--a review. Crit. Rev. Food Sci. Nutr., 1997, 37(1), 47-73.
[58]
Talukdar, M.; Kinget, R. Swelling and drug release behaviour of xanthan gum matrix tablets. Int. J. Pharm., 1995, 120(1), 63-72.
[http://dx.doi.org/10.1016/0378-5173(94)00410-7]
[59]
Prasad, Y.V.; Krishnaiah, Y.S.; Satyanarayana, S. In vitro evaluation of guar gum as a carrier for colon-specific drug delivery. J. Control. Release, 1998, 51(2-3), 281-287.
[http://dx.doi.org/10.1016/S0168-3659(97)00181-8] [PMID: 9685926]
[60]
Salyers, A.A.; Palmer, J.K.; Wilkins, T.D. Degradation of polysaccharides by intestinal bacterial enzymes. Am. J. Clin. Nutr., 1978, 31(10)(Suppl.), S128-S130.
[http://dx.doi.org/10.1093/ajcn/31.10.S128] [PMID: 707363]
[61]
Balascio, J.R.; Palmer, J.K.; Salyers, A.A. Degradation of guar gum by enzymes produced by a bacterium from the human colon. J. Food Biochem., 1981, 5(4), 271-282.
[http://dx.doi.org/10.1111/j.1745-4514.1981.tb00679.x]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy